Biocryst Pharmaceuticals Inc. [BCRX] is -21.70% lower this YTD. Is it still time to buy?

WGO

Biocryst Pharmaceuticals Inc. [NASDAQ: BCRX] price plunged by -7.13 percent to reach at -$0.36. The company report on March 25, 2024 at 4:01 PM that BioCryst to Present at Upcoming Investor Conferences.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The one-year BCRX stock forecast points to a potential upside of 66.06. The average equity rating for BCRX stock is currently 1.33, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Biocryst Pharmaceuticals Inc. [BCRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $13.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for Biocryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 20, 2023. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $9 to $10. The new note on the price target was released on September 18, 2023, representing the official price target for Biocryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $11, while Jefferies analysts kept a Buy rating on BCRX stock.

The Average True Range (ATR) for Biocryst Pharmaceuticals Inc. is set at 0.31, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 2.92.

BCRX Stock Performance Analysis:

Biocryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.48. With this latest performance, BCRX shares dropped by -16.55% in over the last four-week period, additionally sinking by -33.76% over the last 6 months – not to mention a drop of -44.10% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 36.56, with the RSI for the last a single of trading hit 32.21, and the three-weeks RSI is set at 39.51 for Biocryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 5.40, while it was recorded at 5.00 for the last single week of trading, and 6.25 for the last 200 days.

Insight into Biocryst Pharmaceuticals Inc. Fundamentals:

Biocryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.12 and a Current Ratio set at 3.31.

BCRX Stock EPS

With the latest financial reports released by the company, Biocryst Pharmaceuticals Inc. posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.3/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biocryst Pharmaceuticals Inc. go to 44.80%.

Biocryst Pharmaceuticals Inc. [BCRX] Institutonal Ownership Details

The top three institutional holders of BCRX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in BCRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in BCRX stock with ownership which is approximately 5.8386%.